Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment

Authors: Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang, Zhenfei Li

Citation: Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang, Zhenfei Li, Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment, Cell Reports Medicine, 2022, 100608, ISSN 2666-3791, https://doi.org/10.1016/j.xcrm.2022.100608.

Used in this study: Male B-NDG (B-NDG) mice